Pharmaceutical

SOR-007 by Nanology for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

SOR-007 is under clinical development by Nanology and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.

Dec 22, 2023 - 18:00
SOR-007 is under clinical development by Nanology and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.
Read the original article

Tags:

Previous Article

Cadonilimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood o...

Next Article

Jazz Pharmaceuticals Faces Setback in JZP150 Phase II Trial for PTSD Treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: It’s past time to address the problem of indoor air quality. A new technology can help

Opinion: It’s past time to address the problem of indoo...

Jun 28, 2023

NT-175 by Neogene Therapeutics for Head And Neck Squamo...

Dec 26, 2023

STAT+: Hospitals put tech spending on a tight leash, raise the bar for pilots

STAT+: Hospitals put tech spending on a tight leash, ra...

Nov 21, 2023